Company Update (NYSE:BMY): How These Drug Manufacturers BMY, LLY, AZN, and GSK are Performing

[Accesswire] – NEW YORK, NY / ACCESSWIRE / April 21, 2016 / Today, ValuableInvestment.com look at four equities in the Major Drug Manufacturers space: Bristol-Myers Squibb Co. (NYE: BMY), Eli Lilly and Co. (NYSE: LLY), … Read more on this. Bristol-Myers Squibb Company (BMY) , valued at $116.58B, opened at $69.02. During today’s session, BMY traded between $68.88 to $70.24 with the price of the stock fluctuating between $51.82 to $70.87 over the last 52 weeks. BMY shares are currently priced at 28.97x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.18x earnings multiple. And for passive income investors, the company pays shareholders $1.52 per share annually in dividends, yielding 2.21%. In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $0.64 per share, which would be $0.07 worse than the year-ago quarter and a $0.03 sequential increase. What we find to be interesting is that the full-year EPS estimate of $2.39 is a $0.38 better when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.22 Billion. If reported, that would be a 4.46% increase over the year-ago quarter. In terms of ratings, Societe Generale Initiated BMY at Sell (Apr 6, 2016). Previously, Berenberg upgraded BMY from Hold to Buy. The average price target for BMY shares is $71.41, which is 3.46% above where the stock opened this morning. See more in (NYSE:BMY) Similar Articles: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Technical Pointers on Drug Manufacturers – Major Stocks – Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and AstraZeneca Market Update (NYSE:BMY): REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents